The HRD (BRCAness) phenotype can be caused by inactivation of BRCA1/2 genes or some other genes belonging to the same pathway, and is associated with tumor responsiveness to platinum compounds, mitomycin C, PARP inhibitors (PARPi), etc. HRD-deficient cancers cannot efficiently repair DNA double-strand breaks and, therefore, accumulate multiple copy number abnormalities across the genome. The gene discussed is BRCA1; the disease is neoplasm.